Literature DB >> 24856796

Effects of dexmedetomidine on the ratio of T helper 1 to T helper 2 cytokines in patients undergoing laparoscopic cholecystectomy.

Yongsuk Kim1, Sung-Hee Kang2, Tae-Ho Hong3, Mi-La Cho4, Hyo-Jo Han1, Su-Jung Kwon1, Jaemin Lee5.   

Abstract

STUDY
OBJECTIVES: To investigate the effect of dexmedetomidine on T helper 1 (Th1) and T helper 2 (Th2) cytokines and their ratio during and after surgery.
DESIGN: Single-blinded, randomized, placebo-controlled clinical comparison study.
SETTING: Academic medical center. PATIENTS: 46 adult, ASA physical status 1 and 2 patients scheduled for laparoscopic cholecystectomy.
INTERVENTIONS: Patients were randomized to two groups: the dexmedetomidine group (n = 23), in which dexmedetomidine was infused with a 1.0 μg/kg loading dose followed by infusion of 0.5 μg/kg/h; or the saline group (n = 23). MEASUREMENTS: Interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) as Th1 and Th2 cytokines, respectively, were quantified three times: after induction of anesthesia (T0), at the end of peritoneal closure (T1), and 60 minutes after surgery (T2). The IFN-gamma/IL-4 ratio was then calculated. MAIN
RESULTS: The dexmedetomidine group displayed higher levels of IFN-gamma at T1 and T2 (42.30 pg/dL vs 6.91 pg/dL at T1 [P = 0.025]; 40.51 pg/dL vs 8.29 pg/dL at T2 [P = 0.030]) than the saline group. The dexmedetomidine group was also associated with higher ratios of IFN-gamma/IL-4 (1.22 vs 0.32, respectively, at T1 [P = 0.012]; 1.53 vs 0.13, respectively, at T2 [P = 0.012]).
CONCLUSIONS: Dexmedetomidine plays an immunomodulatory role, shifting the Th1/Th2 cytokine balance toward Th1 in patients with surgical and anesthetic stress.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokine; Dexmedetomidine; Surgery; T helper cell

Mesh:

Substances:

Year:  2014        PMID: 24856796     DOI: 10.1016/j.jclinane.2013.11.018

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  8 in total

1.  Dexmedetomidine reduces inflammation in traumatic brain injury by regulating the inflammatory responses of macrophages and splenocytes.

Authors:  Mengyao Ding; Ying Chen; Hengfei Luan; Xiaobao Zhang; Zhibin Zhao; Yong Wu
Journal:  Exp Ther Med       Date:  2019-07-18       Impact factor: 2.447

2.  Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers.

Authors:  H Lavon; P Matzner; A Benbenishty; L Sorski; E Rossene; R Haldar; E Elbaz; J P Cata; V Gottumukkala; S Ben-Eliyahu
Journal:  Br J Anaesth       Date:  2017-11-23       Impact factor: 9.166

3.  Dynamic changes of circulating T-helper cell subsets following severe thoracic trauma.

Authors:  Yi Zhang; Xue Fen Li; Wei Wu; Yu Chen
Journal:  Int J Clin Exp Med       Date:  2015-11-15

4.  Anti-inflammatory Effects of Perioperative Dexmedetomidine Administered as an Adjunct to General Anesthesia: A Meta-analysis.

Authors:  Bo Li; Yalan Li; Shushi Tian; Huixia Wang; Hui Wu; Aihua Zhang; Chengjie Gao
Journal:  Sci Rep       Date:  2015-07-21       Impact factor: 4.379

5.  Long-term use of ceftriaxone sodium induced changes in gut microbiota and immune system.

Authors:  Yanjie Guo; Xuefei Yang; Yane Qi; Shu Wen; Yinhui Liu; Shaoying Tang; Rongsheng Huang; Li Tang
Journal:  Sci Rep       Date:  2017-02-21       Impact factor: 4.379

6.  Dexmedetomidine expands monocytic myeloid-derived suppressor cells and promotes tumour metastasis after lung cancer surgery.

Authors:  Xiaosan Su; Yaodong Fan; Liu Yang; Jie Huang; Fei Qiao; Yu Fang; Jun Wang
Journal:  J Transl Med       Date:  2018-12-11       Impact factor: 5.531

Review 7.  Recent Advances in the Clinical Value and Potential of Dexmedetomidine.

Authors:  Xiaotian Liu; Yueqin Li; Li Kang; Qian Wang
Journal:  J Inflamm Res       Date:  2021-12-30

8.  The effect of dexmedetomidine and clonidine on the inflammatory response in critical illness: a systematic review of animal and human studies.

Authors:  Charles A Flanders; Alistair S Rocke; Stuart A Edwardson; J Kenneth Baillie; Timothy S Walsh
Journal:  Crit Care       Date:  2019-12-11       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.